fitness news
,
Font size Cancer
Melanoma Therapy Advance
– Reported, July 10, 2012
(Ivanhoe Newswire) — It’s summer time and everyone is headed to the beach! The National Cancer Institute estimates that in 2012, there will be more than 76,000 new cases of melanoma, a form of skin cancer, in the United States. Now, Researchers are testing new medications to treat this fast growing disease.
In this study, researchers observed mice without genes responsible for development of an immune cell called T helper cell 17 (TH17). They found that these mice had significant resistance to melanoma tumor growth, suggesting that blockade of the TH17 cell pathway favored tumor inhibition. The researchers also noticed that the mice expressed high amounts of interleukin-9.
“These were unexpected results, which led us to examine a possible contribution of interleukin-9 to cancer growth suppression,” Rahul Purwar, Ph.D., was quoted saying.
Next they treated melanoma-bearing mice with T helper cell 9 (TH9), an immune cell that produces interleukin-9. It was seen that these mice also had a profound resistance to melanoma growth. This is the first reported finding showing an anti-tumor effect of TH9 cells.
The team was able to detect TH9 cells in both normal human blood and skin, specifically in skin-resident memory T cells and memory T cells in peripheral blood mononuclear cells. In contrast, TH9 cells were either absent or present at very low levels in human melanoma. This new finding paves the way for future studies that will assess the role of interleukin-9 and TH9 cells in human cancer therapy.
“Immunotherapy of cancer is coming of age, and there have been exciting recent results in patients with melanoma treated with drugs that stimulate the immune system,” Thomas S. Kupper, MD, the chair of the Brigham and Women’s Hospital Department of Dermatology was quoted saying.
“We hope that our results will also translate to the treatment of melanoma patients, but much work still needs to be done,” Kupper added.
Source: Nature Medicine, July 2012
